

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

Version
11.0

Revision Date:
2025/04/14

SDS Number:
5344796-00018

Date of last issue: 2024/12/04
Date of first issue: 2019/12/09

1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name : Betamethasone / Gentamicin Formulation

Supplier's company name, address and phone number

Company name of supplier : MSD

Address : 1-13-12, Kudan-kita, Chiyoda-ku, Tokyo, Japan

Telephone : 03-6272-1099

E-mail address : EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

GHS classification of chemical product

Serious eye damage/eye irritation : Category 2A

Reproductive toxicity : Category 1B

Specific target organ toxicity - repeated exposure : Category 1 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland)

Short-term (acute) aquatic hazard : Category 2

Long-term (chronic) aquatic hazard : Category 1

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H319 Causes serious eye irritation.
H360D May damage the unborn child.
H372 Causes damage to organs (Pituitary gland, Immune sys-

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

| | | | |
|-----------------|------------------------------|------------------------------|---|
| Version 11.0 | Revision Date: 2025/04/14 | SDS Number: 5344796-00018 | Date of last issue: 2024/12/04 Date of first issue: 2019/12/09 |
|-----------------|------------------------------|------------------------------|---|

tem, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.

H401 Toxic to aquatic life.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements

: Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P260 Do not breathe mist or vapours.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

: Response:

P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

P337 + P313 If eye irritation persists: Get medical advice/ attention.

P391 Collect spillage.

: Storage:

P405 Store locked up.

: Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) | ENCS No. |
|--------------------------|-----------|-----------------------|----------|
| Propylene glycol | 57-55-6 | >= 20 - < 30 | 2-234 |
| Propan-2-ol | 67-63-0 | 16.3 | 2-207 |
| Methyl p-Hydroxybenzoate | 99-76-3 | 1.3 | 3-1585 |
| Gentamicin | 1403-66-3 | >= 0.025 - < 0.1 | - |
| betamethasone | 378-44-9 | >= 0.025 - < 0.1 | - |

SAFETY DATA SHEET




Betamethasone / Gentamicin Formulation

Version
11.0

Revision Date:
2025/04/14

SDS Number:
5344796-00018

Date of last issue: 2024/12/04
Date of first issue: 2019/12/09



4. FIRST AID MEASURES

| | |
|---|---|
| General advice | : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice. |
| If inhaled | : If inhaled, remove to fresh air. Get medical attention. |
| In case of skin contact | : In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. |
| In case of eye contact | : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention. |
| If swallowed | : If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. |
| Most important symptoms and effects, both acute and delayed | : Causes serious eye irritation. May damage the unborn child. Causes damage to organs through prolonged or repeated exposure. |
| Protection of first-aiders | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| Notes to physician | : Treat symptomatically and supportively. |

5. FIREFIGHTING MEASURES

| | |
|---------------------------------------|---|
| Suitable extinguishing media | : Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical |
| Unsuitable extinguishing media | : None known. |
| Specific hazards during fire-fighting | : Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : Carbon oxides |
| Specific extinguishing methods | : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do |

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

Version
11.0

Revision Date:
2025/04/14

SDS Number:
5344796-00018

Date of last issue: 2024/12/04
Date of first issue: 2019/12/09

so.
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing. Do not breathe mist or vapours. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed.

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

| | | | |
|-----------------|------------------------------|------------------------------|---|
| Version 11.0 | Revision Date: 2025/04/14 | SDS Number: 5344796-00018 | Date of last issue: 2024/12/04 Date of first issue: 2019/12/09 |
|-----------------|------------------------------|------------------------------|---|

Avoidance of contact
Hygiene measures

Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

- Oxidizing agents
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Storage

Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Packaging material : Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Threshold limit value and permissible exposure limits for each component in the work environment

| Components | CAS-No. | Value type (Form of exposure) | Control parame- ters / Concentra- tion standard / Permissible con- centration | Basis |
|---------------|-----------|-------------------------------------|---|----------------|
| Propan-2-ol | 67-63-0 | ACL | 200 ppm | JP OEL ISHL |
| | | OEL-C | 400 ppm 980 mg/m ³ | JP OEL JSOH |
| | | TWA | 200 ppm | ACGIH |
| | | STEL | 400 ppm | ACGIH |
| Gentamicin | 1403-66-3 | TWA | 0.1 mg/m ³ (OEB 2) | Internal |
| | | Further information: OTO | | |
| betamethasone | 378-44-9 | TWA | 1 µg/m ³ (OEB 4) | Internal |
| | | Further information: Skin | | |
| | | Wipe limit | 10 µg/100 cm ² | Internal |

Biological occupational exposure limits

| Components | CAS-No. | Target sub- stance | Biological specimen | Sam- pling time | Permissible concentra- tion | Basis |
|------------|---------|-----------------------|------------------------|-----------------------|-----------------------------------|-------|
| | | | | | | |

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

| | | | |
|-----------------|------------------------------|------------------------------|---|
| Version 11.0 | Revision Date: 2025/04/14 | SDS Number: 5344796-00018 | Date of last issue: 2024/12/04 Date of first issue: 2019/12/09 |
|-----------------|------------------------------|------------------------------|---|

| | | | | | | |
|-------------|---------|---------|-------|----------------------------------|---------|-----------|
| Propan-2-ol | 67-63-0 | Acetone | Urine | End of shift at end of work-week | 40 mg/l | ACGIH BEI |
|-------------|---------|---------|-------|----------------------------------|---------|-----------|

Engineering measures : The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type Hand protection : Combined particulates and organic vapour type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

9. PHYSICAL AND CHEMICAL PROPERTIES

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

Version 11.0 Revision Date: 2025/04/14 SDS Number: 5344796-00018 Date of last issue: 2024/12/04
Date of first issue: 2019/12/09

Physical state : liquid

Colour : No data available

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Boiling point, initial boiling point and boiling range : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Lower explosion limit and upper explosion limit / flammability limit

Upper explosion limit / Up- : No data available

per flammability limit

Lower explosion limit / : No data available

Lower flammability limit

Flash point : No data available

Decomposition temperature : No data available

pH : No data available

Evaporation rate : No data available

Auto-ignition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Vapour pressure : No data available

Density and / or relative density

Relative density : No data available

Density : No data available

Relative vapour density : No data available

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

Version 11.0 Revision Date: 2025/04/14 SDS Number: 5344796-00018 Date of last issue: 2024/12/04 Date of first issue: 2019/12/09

| | |
|--------------------------|--|
| Explosive properties | : Not explosive |
| Oxidizing properties | : The substance or mixture is not classified as oxidizing. |
| Molecular weight | : No data available |
| Particle characteristics | |
| Particle size | : Not applicable |

10. STABILITY AND REACTIVITY

| | |
|------------------------------------|--|
| Reactivity | : Not classified as a reactivity hazard. |
| Chemical stability | : Stable under normal conditions. |
| Possibility of hazardous reactions | : Can react with strong oxidizing agents. |
| Conditions to avoid | : None known. |
| Incompatible materials | : Oxidizing agents |
| Hazardous decomposition products | : No hazardous decomposition products are known. |

11. TOXICOLOGICAL INFORMATION

| | |
|--|--|
| Information on likely routes of exposure | : Inhalation Skin contact Ingestion Eye contact |
|--|--|

Acute toxicity

Not classified based on available information.

Components:

Propylene glycol:

| | |
|---------------------------|---|
| Acute oral toxicity | : LD50 (Rat): 22,000 mg/kg |
| Acute inhalation toxicity | : LC50 (Rat): > 44.9 mg/l Exposure time: 4 h Test atmosphere: dust/mist |
| Acute dermal toxicity | : LD50 (Rabbit): > 2,000 mg/kg Assessment: The substance or mixture has no acute dermal toxicity |

Propan-2-ol:

| | |
|---------------------------|--|
| Acute oral toxicity | : LD50 (Rat): > 5,000 mg/kg |
| Acute inhalation toxicity | : LC50 (Rat): > 25 mg/l Exposure time: 6 h Test atmosphere: vapour |

Betamethasone / Gentamicin Formulation

Version 11.0 Revision Date: 2025/04/14 SDS Number: 5344796-00018 Date of last issue: 2024/12/04 Date of first issue: 2019/12/09

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

Methyl p-Hydroxybenzoate:

Acute oral toxicity : LD50 (Rat, male): 2,100 mg/kg
Method: OECD Test Guideline 401

Gentamicin:

Acute oral toxicity : LD50 (Rat): 8,000 - 10,000 mg/kg
LD50 (Mouse): 10,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0.2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : LD50 (Rat): 67 - 96 mg/kg
Application Route: Intravenous
LD50 (Rat): 371 - 384 mg/kg
Application Route: Intramuscular
LDLo (Monkey): 30 mg/kg
Application Route: Intravenous

betamethasone:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
LD50 (Mouse): > 4,500 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0.4 mg/l
Exposure time: 4 h

Skin corrosion/irritation

Not classified based on available information.

Components:**Propylene glycol:**

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Propan-2-ol:

Species : Rabbit
Result : No skin irritation

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

Version
11.0

Revision Date:
2025/04/14

SDS Number:
5344796-00018

Date of last issue: 2024/12/04
Date of first issue: 2019/12/09

Methyl p-Hydroxybenzoate:

| | | |
|---------|---|--------------------|
| Species | : | Rabbit |
| Result | : | No skin irritation |

Gentamicin:

| | | |
|---------|---|----------------------|
| Species | : | Rabbit |
| Result | : | Mild skin irritation |

betamethasone:

| | | |
|---------|---|----------------------|
| Species | : | Rabbit |
| Result | : | Mild skin irritation |

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

Propylene glycol:

| | | |
|---------|---|-------------------------|
| Species | : | Rabbit |
| Result | : | No eye irritation |
| Method | : | OECD Test Guideline 405 |

Propan-2-ol:

| | | |
|---------|---|--|
| Species | : | Rabbit |
| Result | : | Irritation to eyes, reversing within 21 days |

Methyl p-Hydroxybenzoate:

| | | |
|---------|---|-------------------|
| Species | : | Rabbit |
| Result | : | No eye irritation |

Gentamicin:

| | | |
|---------|---|---------------------|
| Species | : | Rabbit |
| Result | : | Mild eye irritation |

betamethasone:

| | | |
|---------|---|-------------------|
| Species | : | Rabbit |
| Result | : | No eye irritation |

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

Version
11.0

Revision Date:
2025/04/14

SDS Number:
5344796-00018

Date of last issue: 2024/12/04
Date of first issue: 2019/12/09

Components:

Propylene glycol:

| | | |
|-----------------|---|-------------------|
| Test Type | : | Maximisation Test |
| Exposure routes | : | Skin contact |
| Species | : | Guinea pig |
| Result | : | negative |

Propan-2-ol:

| | | |
|-----------------|---|-------------------------|
| Test Type | : | Buehler Test |
| Exposure routes | : | Skin contact |
| Species | : | Guinea pig |
| Method | : | OECD Test Guideline 406 |
| Result | : | negative |

Methyl p-Hydroxybenzoate:

| | | |
|-----------------|---|--------------------------|
| Test Type | : | Maurer optimisation test |
| Exposure routes | : | Skin contact |
| Species | : | Guinea pig |
| Method | : | OECD Test Guideline 406 |
| Result | : | negative |

Gentamicin:

| | | |
|---------|---|-------------------|
| Remarks | : | No data available |
|---------|---|-------------------|

betamethasone:

| | | |
|-----------------|---|-----------------|
| Exposure routes | : | Dermal |
| Species | : | Guinea pig |
| Result | : | Weak sensitizer |

Germ cell mutagenicity

Not classified based on available information.

Components:

Propylene glycol:

| | | |
|-----------------------|---|--|
| Genotoxicity in vitro | : | Test Type: Bacterial reverse mutation assay (AMES) Result: negative |
| | | Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative |
| Genotoxicity in vivo | : | Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Result: negative |

Betamethasone / Gentamicin Formulation

| | | | |
|-----------------|------------------------------|------------------------------|---|
| Version 11.0 | Revision Date: 2025/04/14 | SDS Number: 5344796-00018 | Date of last issue: 2024/12/04 Date of first issue: 2019/12/09 |
|-----------------|------------------------------|------------------------------|---|

Propan-2-ol:

| | |
|-----------------------|--|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES) Result: negative |
| | Test Type: In vitro mammalian cell gene mutation test Result: negative |
| Genotoxicity in vivo | : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Result: negative |

Methyl p-Hydroxybenzoate:

| | |
|-----------------------|---|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative |
| | Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: positive |
| Genotoxicity in vivo | : Test Type: Rodent dominant lethal test (germ cell) (in vivo) Species: Rat Application Route: Ingestion Method: OECD Test Guideline 478 Result: negative |

Gentamicin:

| | |
|-----------------------|--|
| Genotoxicity in vitro | : Test Type: In vitro mammalian cell gene mutation test Result: negative |
| | Test Type: Chromosome aberration test in vitro Result: equivocal |
| Genotoxicity in vivo | : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intravenous injection Result: negative |

betamethasone:

| | |
|-----------------------|---|
| Genotoxicity in vitro | : Test Type: Bacterial reverse mutation assay (AMES) Result: negative |
| | Test Type: In vitro mammalian cell gene mutation test Result: negative |
| | Test Type: Chromosome aberration test in vitro Result: positive |

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

Version
11.0

Revision Date:
2025/04/14

SDS Number:
5344796-00018

Date of last issue: 2024/12/04
Date of first issue: 2019/12/09

| | |
|-------------------------------------|--|
| Genotoxicity in vivo | : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Oral Result: equivocal |
| Germ cell mutagenicity - Assessment | : Weight of evidence does not support classification as a germ cell mutagen. |

Carcinogenicity

Not classified based on available information.

Components:

Propylene glycol:

| | |
|-------------------|-------------|
| Species | : Rat |
| Application Route | : Ingestion |
| Exposure time | : 2 Years |
| Result | : negative |

Propan-2-ol:

| | |
|-------------------|---------------------------|
| Species | : Rat |
| Application Route | : inhalation (vapour) |
| Exposure time | : 104 weeks |
| Method | : OECD Test Guideline 451 |
| Result | : negative |

Gentamicin:

| | |
|------------------------------|---------------------|
| Carcinogenicity - Assessment | : No data available |
|------------------------------|---------------------|

Reproductive toxicity

May damage the unborn child.

Components:

Propylene glycol:

| | |
|----------------------|---|
| Effects on fertility | : Test Type: Two-generation reproduction toxicity study Species: Mouse Application Route: Ingestion Result: negative |
|----------------------|---|

Effects on foetal development

| |
|--|
| : Test Type: Embryo-foetal development Species: Mouse Application Route: Ingestion Result: negative |
|--|

Propan-2-ol:

| | |
|----------------------|---|
| Effects on fertility | : Test Type: Two-generation reproduction toxicity study |
|----------------------|---|

Betamethasone / Gentamicin Formulation

Version 11.0 Revision Date: 2025/04/14 SDS Number: 5344796-00018 Date of last issue: 2024/12/04
 Date of first issue: 2019/12/09

| | |
|------------------------------------|--|
| | Species: Rat Application Route: Ingestion Result: negative |
| Effects on foetal development | : Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative |
| Methyl p-Hydroxybenzoate: | |
| Effects on foetal development | : Test Type: Embryo-foetal development Species: Rabbit Application Route: Ingestion Result: negative |
| Gentamicin: | |
| Effects on fertility | : Test Type: Two-generation reproduction toxicity study Species: Rat Fertility: NOAEL: 20 mg/kg body weight Result: No significant adverse effects were reported |
| Effects on foetal development | : Test Type: Embryo-foetal development Species: Rabbit Developmental Toxicity: NOAEL: 3.6 mg/kg body weight Result: No embryo-foetal toxicity |
| | Test Type: Embryo-foetal development Species: Rat Application Route: Intraperitoneal Developmental Toxicity: LOAEL: 75 mg/kg body weight Result: Embryo-foetal toxicity |
| | Test Type: Embryo-foetal development Species: Mouse Application Route: Intraperitoneal Developmental Toxicity: LOAEL: 10 mg/kg body weight Result: foetal mortality, No malformations were observed. |
| | Test Type: Embryo-foetal development Species: Rat Application Route: Intraperitoneal Developmental Toxicity: LOAEL: 50 mg/kg body weight Result: foetal mortality, No malformations were observed. |
| Reproductive toxicity - Assessment | : Positive evidence of adverse effects on development from human epidemiological studies. |
| betamethasone: | |
| Effects on foetal development | : Species: Rabbit Application Route: Intramuscular |

Betamethasone / Gentamicin FormulationVersion
11.0Revision Date:
2025/04/14SDS Number:
5344796-00018Date of last issue: 2024/12/04
Date of first issue: 2019/12/09

Developmental Toxicity: LOAEL: 0.05 mg/kg body weight
Result: Fetotoxicity, Malformations were observed.

Species: Rat
Application Route: Subcutaneous
Developmental Toxicity: LOAEL: 0.42 mg/kg body weight
Result: Malformations were observed.

Species: Mouse
Application Route: Intramuscular
Developmental Toxicity: LOAEL: 1 mg/kg body weight
Result: Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

Components:**Propan-2-ol:**

Assessment : May cause drowsiness or dizziness.

STOT - repeated exposure

Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.

Components:**Gentamicin:**

Target Organs : Kidney, inner ear
Assessment : Causes damage to organs through prolonged or repeated exposure.

betamethasone:

Target Organs : Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Propylene glycol:**

Species : Rat, male
NOAEL : >= 1,700 mg/kg
Application Route : Ingestion
Exposure time : 2 yr

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

Version
11.0

Revision Date:
2025/04/14

SDS Number:
5344796-00018

Date of last issue: 2024/12/04
Date of first issue: 2019/12/09

Propan-2-ol:

| | | |
|-------------------|---|---------------------|
| Species | : | Rat |
| NOAEL | : | 12.5 mg/l |
| Application Route | : | inhalation (vapour) |
| Exposure time | : | 104 Weeks |

Methyl p-Hydroxybenzoate:

| | | |
|-------------------|---|-------------------------|
| Species | : | Rat |
| NOAEL | : | 250 mg/kg |
| LOAEL | : | 1,000 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 28 Days |
| Method | : | OECD Test Guideline 407 |

Gentamicin:

| | | |
|-------------------|---|----------------------|
| Species | : | Dog |
| LOAEL | : | 3 mg/kg |
| Application Route | : | Intramuscular |
| Exposure time | : | 12 Months |
| Target Organs | : | Kidney |
| Symptoms | : | Vomiting, Salivation |

| | | |
|-------------------|---|-------------------|
| Species | : | Monkey |
| LOAEL | : | 50 mg/kg |
| Application Route | : | Subcutaneous |
| Exposure time | : | 3 Weeks |
| Target Organs | : | Kidney, inner ear |

| | | |
|-------------------|---|---------------------------------|
| Species | : | Monkey |
| LOAEL | : | 6 mg/kg |
| Application Route | : | Intramuscular |
| Exposure time | : | 3 Weeks |
| Target Organs | : | Blood, Kidney, inner ear, Liver |

| | | |
|-------------------|---|---------------|
| Species | : | Rat |
| NOAEL | : | 5 mg/kg |
| LOAEL | : | 10 mg/kg |
| Application Route | : | Intramuscular |
| Exposure time | : | 52 Weeks |
| Target Organs | : | Kidney, Blood |

| | | |
|-------------------|---|---------------|
| Species | : | Rat |
| NOAEL | : | 12.5 mg/kg |
| LOAEL | : | 50 mg/kg |
| Application Route | : | Intramuscular |
| Exposure time | : | 13 Weeks |
| Target Organs | : | Kidney |

betamethasone:

| | | |
|---------|---|--------|
| Species | : | Rabbit |
|---------|---|--------|

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

Version 11.0 Revision Date: 2025/04/14 SDS Number: 5344796-00018 Date of last issue: 2024/12/04
Date of first issue: 2019/12/09

| | | |
|-------------------|---|--|
| LOAEL | : | 0.05 % |
| Application Route | : | Skin contact |
| Exposure time | : | 10 - 30 d |
| Target Organs | : | Pituitary gland, Immune system, muscle |
| Species | : | Rat |
| LOAEL | : | 0.05 % |
| Application Route | : | Skin contact |
| Exposure time | : | 8 Weeks |
| Target Organs | : | thymus gland |
| Species | : | Mouse |
| LOAEL | : | 0.1 % |
| Application Route | : | Skin contact |
| Exposure time | : | 8 Weeks |
| Target Organs | : | thymus gland |
| Species | : | Dog |
| LOAEL | : | 0.05 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 28 d |
| Target Organs | : | Blood, thymus gland, Adrenal gland |

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Gentamicin:

| | | |
|-----------|---|--|
| Ingestion | : | Target Organs: Kidney |
| | | Target Organs: inner ear Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal deafness |

betamethasone:

| | | |
|--------------|---|---|
| Inhalation | : | Target Organs: Adrenal gland |
| Skin contact | : | Symptoms: Redness, pruritis, Irritation |

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Propylene glycol:

| | | |
|------------------|---|---|
| Toxicity to fish | : | LC50 (Oncorhynchus mykiss (rainbow trout)): 40,613 mg/l |
|------------------|---|---|

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

Version
11.0

Revision Date:
2025/04/14

SDS Number:
5344796-00018

Date of last issue: 2024/12/04
Date of first issue: 2019/12/09

Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia dubia (water flea)): 18,340 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : ErC50 (Skeletonema costatum (marine diatom)): 19,300 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Ceriodaphnia dubia (water flea)): 13,020 mg/l
Exposure time: 7 d

Toxicity to microorganisms : NOEC (Pseudomonas putida): > 20,000 mg/l
Exposure time: 18 h

Propan-2-ol:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 9,640 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10,000 mg/l
Exposure time: 24 h

Toxicity to microorganisms : EC50 (Pseudomonas putida): > 1,050 mg/l
Exposure time: 16 h

Methyl p-Hydroxybenzoate:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 59.5 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 11.2 mg/l
Exposure time: 48 h
Method: ISO 6341

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): 91 mg/l
Exposure time: 72 h
Method: ISO 8692
EC10 (Pseudokirchneriella subcapitata (green algae)): 31 mg/l
Exposure time: 72 h
Method: ISO 8692

Toxicity to fish (Chronic toxicity) : NOEC (Danio rerio (zebra fish)): 0.024 mg/l
Exposure time: 70 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.2 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

Version
11.0

Revision Date:
2025/04/14

SDS Number:
5344796-00018

Date of last issue: 2024/12/04
Date of first issue: 2019/12/09

Gentamicin:

| | |
|---|---|
| Toxicity to daphnia and other aquatic invertebrates | : EC50 (Daphnia magna (Water flea)): 86 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 |
| | LC50 (Americamysis): 30 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035 |
| Toxicity to algae/aquatic plants | : EC50 (Pseudokirchneriella subcapitata (green algae)): 10 µg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
| | NOEC (Pseudokirchneriella subcapitata (green algae)): 1.5 µg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
| | EC50 (Anabaena flos-aquae (cyanobacterium)): 4.7 µg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
| | NOEC (Anabaena flos-aquae (cyanobacterium)): 1.6 µg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
| M-Factor (Acute aquatic toxicity) | : 100 |
| M-Factor (Chronic aquatic toxicity) | : 1 |
| Toxicity to microorganisms | : EC50: 288.7 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 |

betamethasone:

| | |
|---|--|
| Toxicity to daphnia and other aquatic invertebrates | : EC50 (Americamysis): > 50 mg/l Exposure time: 96 h |
| Toxicity to algae/aquatic plants | : EC50 (Pseudokirchneriella subcapitata (green algae)): > 34 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility |
| | NOEC (Pseudokirchneriella subcapitata (green algae)): 34 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility |

Betamethasone / Gentamicin Formulation

Version 11.0 Revision Date: 2025/04/14 SDS Number: 5344796-00018 Date of last issue: 2024/12/04
Date of first issue: 2019/12/09

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.052 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

NOEC (Oryzias latipes (Japanese medaka)): 0.07 µg/l
Exposure time: 219 d
Method: OECD Test Guideline 229

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 8 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 1,000

Persistence and degradability**Components:****Propylene glycol:**

Biodegradability : Result: Readily biodegradable.
Biodegradation: 98.3 %
Exposure time: 28 d
Method: OECD Test Guideline 301F

Propan-2-ol:

Biodegradability : Result: rapidly degradable
BOD/COD : BOD: 1,19 (BOD5)
COD: 2,23
BOD/COD: 53 %

Methyl p-Hydroxybenzoate:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 89 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Gentamicin:

Biodegradability : Result: rapidly degradable
Biodegradation: 100 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Bioaccumulative potential**Components:****Propylene glycol:**

Partition coefficient: n- : log Pow: -1.07

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

Version 11.0 Revision Date: 2025/04/14 SDS Number: 5344796-00018 Date of last issue: 2024/12/04 Date of first issue: 2019/12/09

||| octanol/water

Method: Regulation (EC) No. 440/2008, Annex, A.8

Propan-2-ol:

||| Partition coefficient: n-octanol/water : log Pow: 0.05

Methyl p-Hydroxybenzoate:

||| Partition coefficient: n-octanol/water : log Pow: 1.98

Gentamicin:

||| Partition coefficient: n-octanol/water : log Pow: < -2

betamethasone:

||| Partition coefficient: n-octanol/water : log Pow: 2.11

Mobility in soil

No data available

Hazardous to the ozone layer

Not applicable

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(betamethasone)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

Version 11.0 Revision Date: 2025/04/14 SDS Number: 5344796-00018 Date of last issue: 2024/12/04
Date of first issue: 2019/12/09

(betamethasone)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 964
Packing instruction (passenger aircraft) : 964
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(betamethasone)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

Refer to section 15 for specific national regulation.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

ERG Code : 171

15. REGULATORY INFORMATION

Related Regulations

Fire Service Law

Not applicable to dangerous materials / designated flammables.

Chemical Substance Control Law

Priority Assessment Chemical Substance

| Chemical name | Number |
|-------------------|--------|
| Propane-1,2-diol | 106 |
| Isopropyl alcohol | 102 |

Industrial Safety and Health Law

Harmful Substances Prohibited from Manufacture

Not applicable

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

Version 11.0 Revision Date: 2025/04/14 SDS Number: 5344796-00018 Date of last issue: 2024/12/04
Date of first issue: 2019/12/09

Harmful Substances Required Permission for Manufacture

Not applicable

Substances Prevented From Impairment of Health

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Not applicable

Substances Subject to be Notified Names

Law Article 57-2 (Ministerial Order Article 34-2 Appended Table 2)

| Chemical name | Concentration (%) | Remarks |
|------------------|-------------------|----------------------|
| Propylene glycol | >=20 - <30 | From April 1st, 2025 |
| Propyl alcohol | 16.3 | - |

Substances Subject to be Indicated Names

Law Article 57 (Ministerial Order Article 30 Appended Table 2)

| Chemical name | Remarks |
|------------------|----------------------|
| Propylene glycol | From April 1st, 2025 |
| Propyl alcohol | - |

Skin and Eye Damage Substances (ISHL MO Art. 594-2)

Not applicable

Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)

Not applicable

Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

Ordinance on Prevention of Lead Poisoning

Not applicable

Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

Ordinance on Prevention of Organic Solvent Poisoning

Organic Solvents Class 2

Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)

Not applicable

Poisonous and Deleterious Substances Control Law

Not applicable

Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof

Class II Designated Chemical Substances

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

Version 11.0 Revision Date: 2025/04/14 SDS Number: 5344796-00018 Date of last issue: 2024/12/04 Date of first issue: 2019/12/09

| Chemical name | Administration number | Concentration (%) |
|--------------------------|-----------------------|-------------------|
| Methyl 4-hydroxybenzoate | 334 | 1.3 |

High Pressure Gas Safety Act

Not applicable

Explosive Control Law

Not applicable

Vessel Safety Law

Miscellaneous dangerous substances and articles (Article 2 and 3 of rules on shipping and storage of dangerous goods and its Attached Table 1)

Aviation Law

Miscellaneous dangerous substances and articles (Article 194 of The Enforcement Rules of Aviation Law and its Attached Table 1)

Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Noxious liquid substance(Category Z)

Pack transportation : Classified as marine pollutant

Narcotics and Psychotropics Control Act

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

Waste Disposal and Public Cleansing Law

Industrial waste

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

In this SDS, if the concentration of substances subject to notification under the Industrial Safety and Health Law is indicated as a range, it includes cases where it is a trade secret.

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

Version
11.0

Revision Date:
2025/04/14

SDS Number:
5344796-00018

Date of last issue: 2024/12/04
Date of first issue: 2019/12/09

Full text of other abbreviations

| | |
|---------------------|--|
| ACGIH | : USA. ACGIH Threshold Limit Values (TLV) |
| ACGIH BEI | : ACGIH - Biological Exposure Indices (BEI) |
| JP OEL ISHL | : Japan. Administrative Control Levels |
| JP OEL JSOH | : Japan. The Japan Society for Occupational Health. Recommendation of Occupational Exposure Limits |
| ACGIH / TWA | : 8-hour, time-weighted average |
| ACGIH / STEL | : Short-term exposure limit |
| JP OEL ISHL / ACL | : Administrative Control level |
| JP OEL JSOH / OEL-C | : Occupational Exposure Limit-Ceiling |

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET



Betamethasone / Gentamicin Formulation

Version
11.0

Revision Date:
2025/04/14

SDS Number:
5344796-00018

Date of last issue: 2024/12/04
Date of first issue: 2019/12/09

JP / EN